Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1996 Sep;74(6):871–873. doi: 10.1038/bjc.1996.450

Reverse transcriptase-polymerase chain reaction for prostate-specific antigen may be a prognostic indicator in breast cancer.

S Lehrer 1, M Terk 1, S P Piccoli 1, H K Song 1, P Lavagnini 1, A A Luderer 1
PMCID: PMC2074722  PMID: 8826851

Abstract

Among women with node-negative breast cancer and small tumours, it is important to identify those with tumours that will recur, so that they may receive adjuvant therapy, while sparing those with tumours that will not recur the hazards of adjuvant treatment. A reverse transcriptase-polymerase chain reaction (RT-PCR) for prostate-specific antigen (PSA) may be used to identify circulating metastatic cells in patients with prostate cancer. Approximately 30% of breast cancer cells also produce PSA. Therefore, we tested the PSA RT-PCR assay on blood specimens from women with breast cancer. We evaluated 78 women at Mount Sinai Medical Center with histologically confirmed breast cancer. Venous blood (5 cm3) from the women was collected in ethylene diaminetetraacetic acid (EDTA)-treated collection tubes and approximately 400 ng of RNA from each sample was subjected to an RT-PCR. We were able to detect the amplified PSA fragment in 18 of 78 women with breast cancer; 7 of the 18 women with the PSA fragment had localised, small, node-negative tumours, both oestrogen receptor (ER) positive and ER negative. We could not detect the amplified PSA fragment in 20 normal women and 22 normal men. We conclude that PSA RT-PCR may be a useful method for determining the presence of circulating metastatic cells in some women with node-negative breast cancer, and therefore the potential for these women to develop recurrent disease and thus benefit from adjuvant therapy.

Full text

PDF
871

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Datta Y. H., Adams P. T., Drobyski W. R., Ethier S. P., Terry V. H., Roth M. S. Sensitive detection of occult breast cancer by the reverse-transcriptase polymerase chain reaction. J Clin Oncol. 1994 Mar;12(3):475–482. doi: 10.1200/JCO.1994.12.3.475. [DOI] [PubMed] [Google Scholar]
  2. Diamandis E. P., Yu H. New biological functions of prostate-specific antigen? J Clin Endocrinol Metab. 1995 May;80(5):1515–1517. doi: 10.1210/jcem.80.5.7538144. [DOI] [PubMed] [Google Scholar]
  3. Diamandis E. P., Yu H., Sutherland D. J. Detection of prostate-specific antigen immunoreactivity in breast tumors. Breast Cancer Res Treat. 1994;32(3):301–310. doi: 10.1007/BF00666007. [DOI] [PubMed] [Google Scholar]
  4. Fisher B. Laboratory and clinical research in breast cancer--a personal adventure: the David A. Karnofsky memorial lecture. Cancer Res. 1980 Nov;40(11):3863–3874. [PubMed] [Google Scholar]
  5. Ghossein R. A., Scher H. I., Gerald W. L., Kelly W. K., Curley T., Amsterdam A., Zhang Z. F., Rosai J. Detection of circulating tumor cells in patients with localized and metastatic prostatic carcinoma: clinical implications. J Clin Oncol. 1995 May;13(5):1195–1200. doi: 10.1200/JCO.1995.13.5.1195. [DOI] [PubMed] [Google Scholar]
  6. Katz A. E., Olsson C. A., Raffo A. J., Cama C., Perlman H., Seaman E., O'Toole K. M., McMahon D., Benson M. C., Buttyan R. Molecular staging of prostate cancer with the use of an enhanced reverse transcriptase-PCR assay. Urology. 1994 Jun;43(6):765–775. doi: 10.1016/0090-4295(94)90132-5. [DOI] [PubMed] [Google Scholar]
  7. Katz A. E., de Vries G. M., Begg M. D., Raffo A. J., Cama C., O'Toole K., Buttyan R., Benson M. C., Olsson C. A. Enhanced reverse transcriptase-polymerase chain reaction for prostate specific antigen as an indicator of true pathologic stage in patients with prostate cancer. Cancer. 1995 Apr 1;75(7):1642–1648. doi: 10.1002/1097-0142(19950401)75:7<1642::aid-cncr2820750714>3.0.co;2-1. [DOI] [PubMed] [Google Scholar]
  8. Leitner S. P., Swern A. S., Weinberger D., Duncan L. J., Hutter R. V. Predictors of recurrence for patients with small (one centimeter or less) localized breast cancer (T1a,b N0 M0). Cancer. 1995 Dec 1;76(11):2266–2274. doi: 10.1002/1097-0142(19951201)76:11<2266::aid-cncr2820761114>3.0.co;2-t. [DOI] [PubMed] [Google Scholar]
  9. Monne M., Croce C. M., Yu H., Diamandis E. P. Molecular characterization of prostate-specific antigen messenger RNA expressed in breast tumors. Cancer Res. 1994 Dec 15;54(24):6344–6347. [PubMed] [Google Scholar]
  10. Moreno J. G., Croce C. M., Fischer R., Monne M., Vihko P., Mulholland S. G., Gomella L. G. Detection of hematogenous micrometastasis in patients with prostate cancer. Cancer Res. 1992 Nov 1;52(21):6110–6112. [PubMed] [Google Scholar]
  11. Noguchi S., Aihara T., Nakamori S., Motomura K., Inaji H., Imaoka S., Koyama H. The detection of breast carcinoma micrometastases in axillary lymph nodes by means of reverse transcriptase-polymerase chain reaction. Cancer. 1994 Sep 1;74(5):1595–1600. doi: 10.1002/1097-0142(19940901)74:5<1595::aid-cncr2820740516>3.0.co;2-l. [DOI] [PubMed] [Google Scholar]
  12. Reynolds T. Breast cancer prognostic factors--the search goes on. J Natl Cancer Inst. 1994 Apr 6;86(7):480–483. doi: 10.1093/jnci/86.7.480. [DOI] [PubMed] [Google Scholar]
  13. Yu H., Diamandis E. P., Sutherland D. J. Immunoreactive prostate-specific antigen levels in female and male breast tumors and its association with steroid hormone receptors and patient age. Clin Biochem. 1994 Apr;27(2):75–79. doi: 10.1016/0009-9120(94)90015-9. [DOI] [PubMed] [Google Scholar]
  14. Yu H., Giai M., Diamandis E. P., Katsaros D., Sutherland D. J., Levesque M. A., Roagna R., Ponzone R., Sismondi P. Prostate-specific antigen is a new favorable prognostic indicator for women with breast cancer. Cancer Res. 1995 May 15;55(10):2104–2110. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES